New clinical study on Bactiguard’s central venous catheter shows promising results

A recent clinical explorative study (link), published in the Journal of Biomedical Materials Research and conducted at the Karolinska University Hospital in Sweden, shows that Bactiguard’s infection prevention central venous catheter – BIP CVC, distributed in Italy by Gada, had significantly fewer adverse events compared to a standard uncoated CVC. The study also shows that Bactiguard’s noble metal alloy does not expose patients or the environment to any risks.

The pilot study was conducted on patients undergoing major abdominal surgery. 34 patients were randomized in two groups, 12 patients received standard CVCs and 22 patients received Bactiguard CVCs. This study confirms that the Bactiguard coating is durable and safe for patients and it shows promising results when it comes to reducing device related complications such as sepsis and thrombosis.